Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $140 to $143.
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $140 to $143.